VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
The collaboration underscores a growing trend in the pharmaceutical industry to leverage AI in drug discovery and development. By applying machine learning algorithms to complex biological data, companies aim to accelerate the identification of viable drug targets and optimize therapeutic candidates. For VERAXA, this partnership could be pivotal in advancing its BiTAC platform, which represents a novel approach to engaging T-cells against tumors while minimizing side effects.
VERAXA's proprietary BiTAC technology is designed to create bispecific antibodies that simultaneously bind to a tumor antigen and a T-cell receptor, thereby redirecting immune cells to attack cancer cells. The addition of AI-driven analysis may help the company select optimal dual-target combinations that are more likely to succeed in clinical trials, potentially reducing the high attrition rates typical in oncology drug development.
To view the full press release, visit https://ibn.fm/GLFg2. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
This announcement comes as VERAXA continues to advance its pipeline of antibody-based therapeutics. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
Forward-looking statements in this article involve risks and uncertainties, including those described in the company's filings with the SEC. Undue reliance should not be placed on these statements, which are based on information available as of the date hereof. All parties undertake no duty to update this information unless required by law.
